Revolution Medicines and Iambic Therapeutics Forge $25M AI-Driven Drug Discovery Partnership

Revolution Medicines has entered into a strategic collaboration with Iambic Therapeutics, leveraging artificial intelligence to accelerate oncology drug discovery. The multi-year technology and research partnership, announced on July 9, 2025, could see Iambic earn up to $25 million in upfront and milestone-based payments.

AI-Powered Platform to Target Challenging Oncology Domains

At the heart of this collaboration is Iambic's AI drug discovery platform, which will be trained using Revolution's proprietary molecular libraries and structures. The partnership aims to enhance drug discovery across novel targets, with a particular focus on oncology targets that have proven difficult to address through conventional approaches.

Iambic will deploy its NeuralPLexer protein-ligand structure prediction model, customized for Revolution's data. Additionally, Revolution will gain access to Iambic's PropANE model, a pre-trained graph neural network designed to evaluate multiple drug properties for lead selection and optimization.

Mark Goldsmith, M.D., Ph.D., CEO of Revolution Medicines, expressed enthusiasm about the collaboration: "The capabilities of Iambic's AI-driven discovery platform, partnered with our unique collection of proprietary data, present an opportunity to rapidly explore oncology targets known to be challenging to address through conventional drug discovery approaches."

Shared Access and Exclusive Rights

Both companies will have access to the AI models developed through this partnership. The agreement also allows each partner to retain rights to a limited number of exclusive targets, potentially accelerating their respective drug discovery pipelines.

Revolution's Focus on RAS-Addicted Cancers

Revolution Medicines specializes in developing therapies for RAS-addicted cancers, with a pipeline of RAS inhibitors designed to suppress variants of RAS proteins. This collaboration with Iambic comes on the heels of a significant funding deal for Revolution. In June 2025, the company secured up to $2 billion from Royalty Pharma in exchange for a share of potential profits from its lead cancer candidate, daraxonrasib.

Daraxonrasib has recently entered a second phase 3 trial in non-small cell lung cancer, while another late-stage study in pancreatic ductal adenocarcinoma is ongoing. These developments underscore Revolution's commitment to advancing novel cancer therapies and highlight the potential impact of this new AI-driven partnership with Iambic Therapeutics.